Compass Therapeutics, Inc.
NASDAQ:CMPX
3.12 (USD) • At close February 4, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Compass Therapeutics, Inc. |
Symbool | CMPX |
Munteenheid | USD |
Prijs | 3.12 |
Beurswaarde | 429,277,680 |
Dividendpercentage | 0% |
52-weken bereik | 0.765 - 3.63 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Thomas J. Schuetz M.D., Ph.D. |
Website | https://www.compasstherapeutics.com |
An error occurred while fetching data.
Over Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)